Literature DB >> 2811888

Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox).

M F Brin1, A Blitzer, S Fahn, W Gould, R E Lovelace.   

Abstract

Adductor spastic dysphonia (SD) is a laryngeal dystonia characterized by a choked, constrained voice pattern with breaks in vocal flow. Treatment with a variety of therapies including speech and pharmacotherapy have minimal benefit; only one-third of patients undergoing recurrent laryngeal nerve section have benefitted at 3 years. We have used local injections of botulinum toxin (Botox) bilaterally into vocalis muscles in 42 patients with SD. Injections were through a teflon-coated hollow electromyography (EMG) recording needle. Unilateral small doses (2.5-3.75 U) were of no clinical benefit. Bilateral small doses resulted in sustained improvement lasting 84.4 +/- 9.3 days. The degree of improvement was 61.1 +/- 4.6%. Common side-effects included a brief period of breathy hypophonia (8.5 +/- 2.5 days) and a mild sensation of choking/aspiration of fluids (1.7 +/- 0.6 days); there were no serious adverse effects. Vocal cord paralysis was not necessary for benefit. Follow-up vocalis muscle EMGs revealed denervation. All patients responded to retreatment (longest follow-up 3.5 years). Patients with prior recurrent laryngeal nerve surgery and residual uncomplicated dysphonia had similar results. Our results indicate that local injection of low-dose Botox is the treatment of choice for SD.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811888     DOI: 10.1002/mds.870040401

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  ["Off-label use" of botulinum toxin preparations in treatment of spasmodic dysphonia. Position of the German Society of Phoniatrics and Pediatric Audiology].

Authors:  M Ptok; R Schönweiler; T Nawka
Journal:  HNO       Date:  2004-01       Impact factor: 1.284

2.  Botulinum toxin.

Authors:  A J Lees
Journal:  BMJ       Date:  1992-11-14

Review 3.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

4.  Atypical somatosensory-motor cortical response during vowel vocalization in spasmodic dysphonia.

Authors:  Sanaz Khosravani; Arash Mahnan; I-Ling Yeh; Peter J Watson; Yang Zhang; George Goding; Jürgen Konczak
Journal:  Clin Neurophysiol       Date:  2019-03-23       Impact factor: 3.708

5.  The consequences of spasmodic dysphonia on communication-related quality of life: a qualitative study of the insider's experiences.

Authors:  Carolyn R Baylor; Kathryn M Yorkston; Tanya L Eadie
Journal:  J Commun Disord       Date:  2005 Sep-Oct       Impact factor: 2.288

6.  The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients' experiences.

Authors:  Carolyn R Baylor; Kathryn M Yorkston; Tanya L Eadie; Nicole C Maronian
Journal:  J Voice       Date:  2006-03-29       Impact factor: 2.009

7.  The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.

Authors:  R Whurr; M Lorch; H Fontana; G Brookes; A Lees; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

8.  Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.

Authors:  J Jankovic; K Schwartz; D T Donovan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

Review 9.  Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30-year experience.

Authors:  Andrew Blitzer; Mitchell F Brin; Kristina Simonyan; Laurie J Ozelius; Steven J Frucht
Journal:  Laryngoscope       Date:  2017-12-08       Impact factor: 3.325

10.  Treatment of cervical dystonia hand spasms and laryngeal dystonia with botulinum toxin.

Authors:  A J Lees; N Turjanski; J Rivest; R Whurr; M Lorch; G Brookes
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.